AIM ImmunoTech plans phase 3 pancreatic cancer trial for Ampligen

April 16, 2026 11:45 AM

AIM ImmunoTech Inc. (NYSE American: AIM) announced plans to advance its drug Ampligen into a Phase 3 clinical trial for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found